The impact of adjuvant treatment with external beam radiotherapy and vaginal brachytherapy on health-related quality of life in patients with early-stage endometrioid endometrial carcinoma — initial results of a prospective study
| Autor: | Adam Kluska, Bartłomiej Tomasik, Małgorzata Moszyńska-Zielińska, Jacek Fijuth, Anna Stanislawek, Jolanta Luniewska-Bury, Natalia Tracz, Leszek Gottwald, Leszek Zytko |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Hysterectomy business.industry medicine.medical_treatment Endometrial cancer Brachytherapy Urology Obstetrics and Gynecology medicine.disease humanities Radiation therapy Quality of life Medicine External beam radiotherapy business Prospective cohort study Radiation treatment planning |
| Zdroj: | Ginekologia Polska. 93:195-202 |
| ISSN: | 2543-6767 0017-0011 |
| Popis: | Objectives: Our study evaluates the impact of adjuvant treatment with external beam radiotherapy (EBRT) combined with vaginal high-dose-rate brachytherapy (HDR BT) on health-related quality of life (HRQL) in patients with early-stage endometrioid endometrial carcinoma. Material and methods: We assessed HRQL of patients based on the EORTC QLQ-C30 questionnaire, with endometrial cancer specific HRQL module — EORTC QLQ-EN24. From March 2019 to April 2020 we enrolled 20 patients with early-stage endometrioid endometrial carcinoma, qualified for adjuvant treatment after hysterectomy. We compared the scores measured with the questionnaires at the beginning and at the end of the treatment. Results: There was a statistically significant decrease in the mean of global health status/quality of life assessed according to the EORTC QLQ-C30 scale, from 62.25 ± 13.12 at the beginning of the adjuvant radiotherapy to 55.85 ± 14.68 at the end of the treatment (p = 0.047). The mean appetite loss score was higher at the onset of the treatment as compared to its value after EBRT, 19.9 ± 27.33 vs 11.6 ± 19.52 (p = 0.043). Similarly to the mean constipation score, which was 29.85 ± 30.40 vs 11.6 ± 19.52 (p = 0.013). The mean diarrhoea symptom scale increased from 16.55 ± 20.16 to 56.75 ± 36.10 (p = 0.001). In the EORTC QLQ-EN24 scales, gastrointestinal symptoms scores were higher at the end of the treatment, (with the mean of 26.45 ± 22.76) as compared to 14.30 ± 16.52 at the beginning of EBRT (p = 0.003). Conclusions: Patients who receive adjuvant radiotherapy have decreased quality of life during the treatment reporting more serious gastrointestinal symptoms. The potential risk of treatment-related toxicity should be taken into account during the treatment planning process in order to minimize the deterioration of HRQL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|